Dragonfly Therapeutics CPH ApS — Credit Rating and Financial Key Figures

Dragonfly Therapeutics CPH ApS (CVR number: 41557958) is a company from BALLERUP. The company recorded a gross profit of 25.8 mDKK in 2022. The operating profit was -7933.2 kDKK, while net earnings were -8054.4 kDKK. The profitability of the company measured by Return on Assets (ROA) was -20 %, which can be considered poor and Return on Equity (ROE) was -33.6 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -11.5 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Dragonfly Therapeutics CPH ApS's liquidity measured by quick ratio was 0.9 which is at a modest level. Thus, the company's liquid assets are in relative balance with its short-term liabilities, indicating a moderate liquidity position. While it's likely to meet its current obligations, financial flexibility may be constrained, and unexpected costs could pose challenges.